5:11 PM ET
8-K
Clinical Trial Data
Acadia Pharmaceuticals Clinical Trial Data
Acadia Pharmaceuticals announced Phase 3 enabling topline results from the Phase 2 portion of its RADIANT trial evaluating remlifanserin for Alzheimer’s disease psychosis (ADP). While the 60 mg dose narrowly missed the primary endpoint (p=0.0603), it showed nominal significance on a key secondary endpoint and a favorable safety profile, leading the company to continue its Phase 3 program with the 60 mg dose.
- Earnings call
- Sep 24, 2026, 8:00 AM ET